<DOC>
	<DOCNO>NCT00530816</DOCNO>
	<brief_summary>To evaluate best overall response rate , safety tolerability carfilzomib patient relapse refractory multiple myeloma .</brief_summary>
	<brief_title>Phase 2 Study Carfilzomib Relapsed Multiple Myeloma</brief_title>
	<detailed_description>Two group patient multiple myeloma initially study : bortezomib-naïve bortezomib-treated . Following Amendment 2 , bortezomib-naïve patient enrol . Study result report 2 part , depend whether patient receive prior bortezomib .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>Disease Related Multiple myeloma Subjects must measurable disease , define one following : Serum Mprotein ≥ 1 g/dL Urine Mprotein ≥ 200 mg/24 hour Subjects must responsive ( i.e. , achieve minimal response [ MR ] well ) standard , first line therapy Relapsed and/or refractory progressive disease least one , three , prior therapeutic treatment regimens multiple myeloma . Refractory disease define ≤ 25 % response progression therapy within 60 day completion therapy . Induction therapy stem cell transplant consider one regimen Demographic Males females ≥18 year age Life expectancy three month Eastern Cooperative Oncology Group ( ECOG ) Performance Status 02 Laboratory Adequate hepatic function , bilirubin &lt; 2.0 time upper limit normal , aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 3.0 time upper limit normal Uric acid , elevate , must correct within laboratory normal range prior dose Total white blood cell ( WBC ) count ≥ 2,000/mm³ , absolute neutrophil count &gt; 1,000/mm³ , hemoglobin ≥ 8.0 g/dL , platelet count &gt; 50,000/mm³ Subjects platelet transfusion independent Screening absolute neutrophil count ( ANC ) independent granulocyte colony stimulate factor ( GCSF ) granulocyte macrophage colony stimulate factor ( GMCSF ) support ≥ 1 week pegylated GCSF ≥ 2 week Subjects may receive red blood cell ( RBC ) transfusion receive supportive care erythropoietin darbepoetin accordance institutional guideline Calculated measured creatinine clearance ≥ 30 mL/minute , calculate use formula Cockcroft Gault [ ( 140 Age ) X Mass ( kg ) / ( 72 X Creatinine mg/dL ) ] . Multiply result 0.85 female . Serum creatinine ≤ 2 mg/dL Ethical / Other Written inform consent accordance federal , local , institutional guideline Female subject childbearing potential must negative serum pregnancy test within seven day first dose agree use dual method contraception 3 month follow last dose drug . Post menopausal female ( &gt; 45 year old without menses &gt; 1 year ) surgically sterilize female exempt pregnancy test . Male subject must use effective barrier method contraception study 3 month follow last dose sexually active female childbearing potential . Subjects must able receive outpatient treatment laboratory monitor institute administers agent . Disease Related Multiple Myeloma Immunoglobulin M ( IgM ) Subjects previously treat proteasome inhibitor ( Part 2 Proteasome Inhibitor Naïve , criterion add Amendment 2 ) Subjects must primary refractory standard firstline therapy Subjects nonsecretory multiple myeloma , define &lt; 1 g/dL Mprotein serum , &lt; 200 mg/24 hour Mprotein urine Subjects disease measurable serum free light chain ( SFLC ) analysis Glucocorticoid therapy ( prednisone &gt; 10 mg/day orally equivalent ) within last three week POEMS syndrome ( polyneuropathy , organomegaly , endocrinopathy , monoclonal protein , skin change ) Plasma cell leukemia Chemotherapy approve investigative anticancer therapeutic , include steroid therapy , within three week prior first dose Radiation therapy immunotherapy previous four week ; localize radiation therapy within 1 week prior first dose Participation investigational therapeutic study within three week within five drug halflives ( t1/2 ) prior first dose , whichever time great Prior treatment carfilzomib Concurrent Conditions Major surgery within three week Day 1 Congestive heart failure ( New York Heart Association class III IV ) , symptomatic ischemia , conduction abnormality uncontrolled conventional intervention , myocardial infarction previous six month Acute active infection require systemic antibiotic , antiviral antifungal within 2 week prior first dose Known suspected human immunodeficiency ( HIV ) infection subject HIV seropositive Active hepatitis A , B , C infection Nonhematologic malignancy within past three year except ) adequately treat basal cell squamous cell skin cancer , b ) carcinoma situ cervix , c ) prostate cancer &lt; Gleason Grade 6 stable prostatespecific antigen ( PSA ) Subjects treatment related myelodysplastic syndrome Significant neuropathy ( Grade 3 , 4 Grade 2 pain ) time study initiation Subjects know contraindication receive allopurinol Subjects require program oral intravenous fluid hydration contraindicate , e.g. , due preexist pulmonary , cardiac , renal impairment Subjects know suspected amyloidosis Subjects pleural effusion require thoracentesis ascites require paracentesis Any clinically significant medical disease condition , Investigator 's opinion , may interfere protocol adherence subject 's ability give inform consent Ethical / Other Female subject pregnant lactate Serious psychiatric medical condition could interfere treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>